Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Cytarabine + MYCi975|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Cytarabine||Cytosar-U||Ara-C||Cytosar-U (cytarabine) is a cytidine analog that, when incorporated into DNA, inhibits DNA synthesis and repair (PMID: 32524309).|
|MYCi975||NUCC-0200975||c-MYC Inhibitor 9||MYCi975 is an inhibitor of MYC that blocks the interaction between Myc and Max, which leads to reduced Myc stability, thereby potentially enhancing the antitumor immune response, and inhibiting colony formation and tumor growth (PMID: 31679823).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||leukemia||not applicable||Cytarabine + MYCi975||Preclinical - Cell line xenograft||Actionable||In a preclinical study, MYCi975 and Cytosar-U (cytarabine) combination treatment synergistically inhibited tumor growth in a cell line xenograft model of leukemia (PMID: 31679823).||31679823|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|